Latest From Tarsus Pharmaceuticals
Recent venture funding for emerging biopharma companies, including CF PharmTech, Codagenix, Empirico, Epirium, Generation, Kyverna, NorthSea, VectivBio, Rig and Tarsus.
Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans.
For its biggest antibody deal to date, Pfizer choose Medarex, which insists on non-exclusive agreements, leaving the biotech free to work with other partners on any given target. In doing so, Pfizer reckoned that the potential for competition with respect to a particular target was outweighed by the greater access to targets which Medarex's deal model provides.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Tarsus Pharmaceuticals
- Senior Management
Bobby Azamian, CEO
Maaza Martin, Dir., Mktg.
- Contact Info
Phone: (949) 409-9820
19782 MacArthur Blvd., Ste. 285
Irvine, CA 92612
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.